{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=opiates&page=2",
    "query": {
      "intervention": "opiates",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=opiates&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T22:04:26.275Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01677065",
      "title": "A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxycodone controlled-release test formulation",
          "type": "DRUG"
        },
        {
          "name": "Immediate-release reference drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677065"
    },
    {
      "nct_id": "NCT00000207",
      "title": "Multicenter Clinical Trial of Buprenorphine - 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "1992-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000207"
    },
    {
      "nct_id": "NCT04571619",
      "title": "HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Chronic Pain",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "Pain Coping Skills Training (PCST)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2021-01-03",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 16,
      "location_summary": "West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04571619"
    },
    {
      "nct_id": "NCT07284472",
      "title": "Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Agitation Associated With Alzheimer's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "EXV-802",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EXV-801",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exciva GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-02-02",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 9,
      "location_summary": "Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 6 more",
      "locations": [
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Flowood",
          "state": "Mississippi"
        },
        {
          "city": "Chesterfield",
          "state": "Missouri"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284472"
    },
    {
      "nct_id": "NCT00227357",
      "title": "The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "AIDS",
        "Opiate Dependence",
        "Post-Traumatic Stress Disorders"
      ],
      "interventions": [
        {
          "name": "On-site - buprenorphine/naloxone (Suboxone)",
          "type": "DRUG"
        },
        {
          "name": "Off-site - methadone or no agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ruth M. Rothstein CORE Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2005-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2010-06-07",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227357"
    },
    {
      "nct_id": "NCT06340932",
      "title": "Impact of Opioid Avoidance Protocol for ACL Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ACL Tear",
        "Post Operative Pain"
      ],
      "interventions": [
        {
          "name": "Iovera",
          "type": "DEVICE"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Tramadol",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen 500Mg Cap",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Matthew Varacallo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2024-04-27",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "DuBois, Pennsylvania",
      "locations": [
        {
          "city": "DuBois",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06340932"
    },
    {
      "nct_id": "NCT00502216",
      "title": "Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Smoking",
        "Nicotine Dependence"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-07",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00502216"
    },
    {
      "nct_id": "NCT00896285",
      "title": "The First Therapeutic Intervention in Malignant Pleural Effusion Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Pleural Effusion",
        "Pleural Effusion"
      ],
      "interventions": [
        {
          "name": "Large bore chest drain + NSAID based analgesic regimen",
          "type": "OTHER"
        },
        {
          "name": "Small bore chest drain + NSAID based analgesic regimen",
          "type": "OTHER"
        },
        {
          "name": "Large bore chest drain + opiate based analgesic regimen",
          "type": "OTHER"
        },
        {
          "name": "Small bore chest drain + opiate based analgesic regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-04",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-07-20",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896285"
    },
    {
      "nct_id": "NCT00055549",
      "title": "Dextromethorphan to Treat Patients With Voice Spasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Voice Disorders"
      ],
      "interventions": [
        {
          "name": "Dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "Lorazepam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 65,
      "start_date": "2003-03-04",
      "completion_date": "2009-11-13",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055549"
    },
    {
      "nct_id": "NCT02911597",
      "title": "Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2016-09",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-04-24",
      "last_synced_at": "2026-09-12T22:04:26.275Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02911597"
    }
  ]
}